Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

13.30
+0.57004.48%
Post-market: 13.300.00000.00%19:26 EST
Volume:966.66K
Turnover:12.76M
Market Cap:1.10B
PE:-4.44
High:13.42
Open:13.04
Low:12.73
Close:12.73
52wk High:19.11
52wk Low:3.91
Shares:82.79M
Float Shares:59.91M
Volume Ratio:0.59
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9984
EPS(LYR):-2.3246
ROE:-98.23%
ROA:-49.39%
PB:5.50
PE(LYR):-5.72

Loading ...

EyePoint Inc. nimmt am Guggenheim Emerging Outlook: Biotech Summit teil

Reuters
·
Feb 05

EyePoint Grants Stock Options to New Employees as Inducement Awards

Reuters
·
Jan 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 16

EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target

TIPRANKS
·
Jan 08

EyePoint Inc. Chief Medical Officer Ramiro Ribeiro Reports Disposal of Common Shares

Reuters
·
Jan 08

EyePoint Inc. to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

GlobeNewswire
·
Jan 07

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

EyePoint (EYPT) Valuation Check as Upgraded Earnings Estimates Fuel Strong Share Price Momentum

Simply Wall St.
·
Dec 24, 2025

BRIEF-Eyepoint Reports Inducement Grants Under NASDAQ Listing Rule

Reuters
·
Dec 16, 2025

EyePoint Grants Stock Options to New Employees as Inducement Awards

Reuters
·
Dec 16, 2025

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 16, 2025

After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar

Simply Wall St.
·
Dec 13, 2025

Cormorant Asset Management Reports Sale of EyePoint Pharmaceuticals Common Shares

Reuters
·
Dec 09, 2025

EyePoint Pharmaceuticals Inc - Changes Name to EyePoint, Inc. - SEC Filing

THOMSON REUTERS
·
Dec 08, 2025

EyePoint Pharmaceuticals Amends Bylaws to Reflect Name Change

Reuters
·
Dec 08, 2025

EyePoint Pharmaceuticals Director Nancy Lurker Reports Disposal of Common Shares

Reuters
·
Dec 06, 2025

Director Nancy Lurker Reports Sale of EyePoint Pharmaceuticals Inc. Common Shares

Reuters
·
Dec 02, 2025

EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU

Simply Wall St.
·
Nov 29, 2025